Iterating iTeos

How an MPM-led series B aligns iTeos for a potential IPO

With a new office in the U.S. and $75 million in fresh series B funding to support clinical development of at least two candidates, Belgian cancer company iTeos Therapeutics S.A. is considering a U.S. IPO as its next big step.

MPM Capital led iTeos’ new round, which also included HBM Partners, 6 Dimensions Capital, Curative Ventures and SFPI as well

Read the full 596 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE